Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Immunocore Ltd
- Registration Number
- NCT02535078
- Locations
- ๐บ๐ธ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
๐บ๐ธThomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 84
- Registration Number
- NCT01211262
- Locations
- ๐บ๐ธ
Yale Cancer Center, New Haven, Connecticut, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
๐ฌ๐งQueen Elizabeth Hospital, Birmingham, United Kingdom
ยฉ Copyright 2024. All Rights Reserved by MedPath